Source comparison
Melanotan-1 Downstream Effects: Research vs Clinical Comparison
Photoprotection (EPP) UV tolerance Eumelanin synthesis in melanocytes 50–75% reduction in phototoxic episodes FDA-approved (Scenesse implant) Inflammatory skin disease (vitiligo) Pigment restoration + immune modulation Melanogenesis + cytokine suppression in k
This comparison does not assign a generated winner or score.
- Photoprotection (EPP)
- UV tolerance
- Eumelanin synthesis in melanocytes
- 50–75% reduction in phototoxic episodes
- FDA-approved (Scenesse implant)
- Inflammatory skin disease (vitiligo)
- Pigment restoration + immune modulation
- Melanogenesis + cytokine suppression in keratinocytes
- Variable repigmentation; reduced inflammatory markers
- Phase II–III trials
- Neuroprotection (neuroinflammation models)
- CNS immune modulation
- cAMP elevation in microglia and astrocytes
- Reduced microglial activation, lower pro-inflammatory cytokine levels
- Preclinical (animal models)
- Metabolic signaling (adipocytes)
- Lipid metabolism and insulin sensitivity
- MC1R activation increases lipolysis, modulates leptin
- Increased fatty acid oxidation in vitro; clinical data limited
- Early research
- UV-induced DNA damage
- DNA repair enzyme expression
- PKA-mediated upregulation of NER pathway components
- 40% reduction in cyclobutane pyrimidine dimers post-UV
- Published research (human keratinocytes)
- Assessment
- Melanotan-1 produces therapeutic effects in contexts where pigmentation is irrelevant, confirming that MC1R downstream signaling extends beyond melanocytes. The cAMP → PKA → transcriptional modulation pathway is tissue-agnostic. Outcomes depend on which genes are under CREB or NF-κB control in the target cell.